- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/645 - Secrétines
Détention brevets de la classe C07K 14/645
Brevets de cette classe: 53
Historique des publications depuis 10 ans
|
5
|
4
|
7
|
7
|
2
|
4
|
3
|
8
|
6
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Antag Therapeutics ApS | 13 |
5 |
| Eli Lilly and Company | 4114 |
4 |
| Novo Nordisk A/S | 2284 |
4 |
| Adda Biotech Inc. | 6 |
3 |
| Sunshine Lake Pharma Co., Ltd. | 629 |
3 |
| Shattuck Labs, Inc. | 122 |
3 |
| Hanmi Pharm. Co., Ltd. | 602 |
2 |
| Indiana University Research and Technology Corporation | 781 |
2 |
| University of Copenhagen | 441 |
2 |
| Zealand Pharma A/S | 269 |
2 |
| Shanghai Minwei Biotechnology Co., Ltd | 11 |
2 |
| The Board of Trustees of the Leland Stanford Junior University | 6697 |
1 |
| The Trustees of Columbia University in the City of New York | 3649 |
1 |
| Amylyx Pharmaceuticals Inc. | 127 |
1 |
| Bolder Biotechnology, Inc. | 14 |
1 |
| CEM Corporation | 103 |
1 |
| Centre hospitalier universitaire D'angers | 59 |
1 |
| Eiger BioPharmaceuticals, Inc. | 32 |
1 |
| Han, Jie | 9 |
1 |
| Innovation Ulster Limited | 18 |
1 |
| Autres propriétaires | 12 |